MENOSTAR by Bayer is characteristics. First approved in 2004.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
MENOSTAR is an estradiol transdermal patch approved in 2004 for hormone replacement therapy in postmenopausal women. It delivers estradiol, the primary intracellular human estrogen, which acts through nuclear receptor binding to alleviate vasomotor symptoms and other menopausal manifestations. The drug works by restoring circulating estrogen levels and suppressing elevated gonadotropins (LH and FSH) characteristic of postmenopause.
Mature, declining product with minimal commercial momentum; brand support and team size likely contracting as patent expiration approaches.
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Worked on MENOSTAR at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MENOSTAR offers limited career growth potential given its LOE-approaching status and minimal linked job postings. Roles are likely focused on defending market share against generics and non-hormonal competitors rather than driving innovation or expansion.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo